• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在假定的钙通道内存在多个受体位点的证据。

Evidence of multiple receptor sites within the putative calcium channel.

作者信息

Ferry D R, Glossmann H

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 1982 Oct;321(1):80-3. doi: 10.1007/BF00586355.

DOI:10.1007/BF00586355
PMID:6292744
Abstract

[3H]-Nimodipine a potent calcium channel blocker, binds to an apparently homogenous population of receptors in guinea-pig brain membranes (KD=0.62 nM, Hill coefficient or approximately 1.0). Diltiazem (10(-5) M) lowers the KD for [3H]-nimodipine by a factor of 3 without changing the maximum number of binding sites. Diltiazem decreased the dissociation rate constant of the nimodipine-receptor complex from 0.18 min-1 to 0.049 min-1 and altered the pharmacological profile as revealed by displacement studies with (-) and (+) verapamil, (-) and (+) prenylamine and 1,4 dihydropyridines. In conclusion [3H]-nimodipine binding can be utilized as a tool to evaluate complex molecular interactions between calcium channel blockers.

摘要

[3H] - 尼莫地平是一种强效钙通道阻滞剂,它与豚鼠脑膜中明显同质的受体群体结合(解离常数KD = 0.62 nM,希尔系数约为1.0)。地尔硫卓(10^(-5) M)可使[3H] - 尼莫地平的KD降低3倍,而不改变结合位点的最大数量。地尔硫卓将尼莫地平 - 受体复合物的解离速率常数从0.18 min^(-1)降至0.049 min^(-1),并改变了药理学特征,这在使用(-)和(+)维拉帕米、(-)和(+)普尼拉明以及1,4 - 二氢吡啶进行的置换研究中得到了揭示。总之,[3H] - 尼莫地平结合可作为评估钙通道阻滞剂之间复杂分子相互作用的一种工具。

相似文献

1
Evidence of multiple receptor sites within the putative calcium channel.在假定的钙通道内存在多个受体位点的证据。
Naunyn Schmiedebergs Arch Pharmacol. 1982 Oct;321(1):80-3. doi: 10.1007/BF00586355.
2
Molecular approach to the calcium channel.钙通道的分子研究方法。
Adv Myocardiol. 1985;5:41-76. doi: 10.1007/978-1-4757-1287-2_4.
3
Effects of Ca2+ channel blockers on Ca2+ translocation across synaptosomal membranes.钙离子通道阻滞剂对钙离子跨突触体膜转运的影响。
J Neurochem. 1986 Dec;47(6):1774-84. doi: 10.1111/j.1471-4159.1986.tb13088.x.
4
Identification of voltage operated calcium channels by binding studies: differentiation of subclasses of calcium antagonist drugs with 3H-nimodipine radioligand binding.通过结合研究鉴定电压门控钙通道:用3H-尼莫地平放射性配体结合法区分钙拮抗剂药物的亚类。
J Recept Res. 1983;3(1-2):177-90. doi: 10.3109/10799898309041932.
5
Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity.地尔硫䓬、硝苯地平及维拉帕米的变时性、变力性和血管舒张作用。生理反应与膜受体活性的比较研究。
Circ Res. 1983 Feb;52(2 Pt 2):I29-39.
6
Calcium channels: evidence for oligomeric nature by target size analysis.钙通道:通过靶点大小分析证明其寡聚性质
EMBO J. 1983;2(10):1729-32. doi: 10.1002/j.1460-2075.1983.tb01649.x.
7
Solubilization and partial purification of putative calcium channels labelled with [3H]-nimodipine.用[3H]-尼莫地平标记的假定钙通道的增溶和部分纯化。
Naunyn Schmiedebergs Arch Pharmacol. 1983 Aug;323(4):279-91. doi: 10.1007/BF00512465.
8
Mechanism of calcium channel inhibition by phenytoin: comparison with classical calcium channel antagonists.苯妥英对钙通道的抑制机制:与经典钙通道拮抗剂的比较。
J Pharmacol Exp Ther. 1985 Nov;235(2):407-11.
9
Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, [125I]iodipine.钙通道的分子药理学:关于亚型、多个药物受体位点、通道亚基的证据以及放射性碘化的1,4 - 二氢吡啶钙通道标记物[125I]碘尼地平的研发。
J Cardiovasc Pharmacol. 1984;6 Suppl 4:S608-21.
10
Differential labelling of putative skeletal muscle calcium channels by [3H]-nifedipine, [3H]-nitrendipine, [3H]-nimodipine and [3H]-PN 200 110.用[3H]-硝苯地平、[3H]-尼群地平、[3H]-尼莫地平和[3H]-PN 200 110对假定的骨骼肌钙通道进行差异标记。
Naunyn Schmiedebergs Arch Pharmacol. 1983 Jul;323(3):276-7. doi: 10.1007/BF00497674.

引用本文的文献

1
International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands.国际基础与临床药理学联合会。XC。多位点药理学:受体变构作用及变构配体命名法建议。
Pharmacol Rev. 2014 Oct;66(4):918-47. doi: 10.1124/pr.114.008862.
2
A calmodulin-like ca receptor in the ca channel.钙通道中一种类钙调蛋白的钙受体。
Biophys J. 1984 Jan;45(1):134-6. doi: 10.1016/S0006-3495(84)84138-7.
3
Proceedings of the British Pharmacological Society. University of Leicester, 6th-8th July, 1983. Abstracts.

本文引用的文献

1
[3H]-Nimodipine and [3H]-nitrendipine as tools to directly identify the sites of action of 1,4-dihydropyridine calcium antagonists in guinea-pig tissues. Tissue-specific effects of anions and ionic strength.[3H]-尼莫地平和[3H]-尼群地平作为直接鉴定豚鼠组织中1,4-二氢吡啶类钙拮抗剂作用位点的工具。阴离子和离子强度的组织特异性效应。
Arzneimittelforschung. 1982;32(4):361-3.
2
Behavioral effects of nimodipine in animals.尼莫地平对动物的行为影响。
Arzneimittelforschung. 1982;32(4):347-60.
3
The effects of nimodipine, its optical isomers and metabolites on isolated vascular smooth muscle.
英国药理学会会议记录。莱斯特大学,1983年7月6日至8日。摘要。
Br J Pharmacol. 1983 Sep;80 Suppl(Suppl):426P-594P.
4
Functional interactions of calcium-antagonists in K+-depolarized smooth muscle.钙拮抗剂在钾离子去极化平滑肌中的功能相互作用。
Br J Pharmacol. 1983 Nov;80(3):485-8. doi: 10.1111/j.1476-5381.1983.tb10719.x.
5
A unitary mechanism of calcium antagonist drug action.钙拮抗剂药物作用的单一机制。
Proc Natl Acad Sci U S A. 1983 Feb;80(3):860-4. doi: 10.1073/pnas.80.3.860.
6
Changing surface charge with salicylate differentiates between subgroups of calcium-antagonists.用阿司匹林改变表面电荷可区分钙拮抗剂的亚组。
Br J Pharmacol. 1984 Sep;83(1):211-20. doi: 10.1111/j.1476-5381.1984.tb10137.x.
7
125I-iodipine, a new high affinity ligand for the putative calcium channel.125I-碘地平,一种用于假定钙通道的新型高亲和力配体。
Naunyn Schmiedebergs Arch Pharmacol. 1984 Feb;325(2):186-9. doi: 10.1007/BF00506200.
8
Calcium channels: evidence for oligomeric nature by target size analysis.钙通道:通过靶点大小分析证明其寡聚性质
EMBO J. 1983;2(10):1729-32. doi: 10.1002/j.1460-2075.1983.tb01649.x.
9
Putative calcium channel molecular weight determination by target size analysis.
Naunyn Schmiedebergs Arch Pharmacol. 1983 Aug;323(4):292-7. doi: 10.1007/BF00512466.
10
Solubilization and partial purification of putative calcium channels labelled with [3H]-nimodipine.用[3H]-尼莫地平标记的假定钙通道的增溶和部分纯化。
Naunyn Schmiedebergs Arch Pharmacol. 1983 Aug;323(4):279-91. doi: 10.1007/BF00512465.
尼莫地平及其光学异构体和代谢产物对离体血管平滑肌的作用。
Arzneimittelforschung. 1982;32(4):338-46.
4
[3H]-Nitrendipine, a potent calcium antagonist, binds with high affinity to cardiac membranes.[3H]-尼群地平,一种强效钙拮抗剂,与心肌膜具有高亲和力结合。
Arzneimittelforschung. 1981;31(12):2064-7.
5
Stereoselective and non-stereoselective effects of D 600 (methoxyverapamil) in smooth muscle preparations.D600(甲氧维拉帕米)在平滑肌制剂中的立体选择性和非立体选择性作用。
Eur J Pharmacol. 1981 Nov 19;76(1):67-72. doi: 10.1016/0014-2999(81)90010-8.
6
Identification of voltage operated calcium channels by binding studies: differentiation of subclasses of calcium antagonist drugs with 3H-nimodipine radioligand binding.通过结合研究鉴定电压门控钙通道:用3H-尼莫地平放射性配体结合法区分钙拮抗剂药物的亚类。
J Recept Res. 1983;3(1-2):177-90. doi: 10.3109/10799898309041932.
7
Ligand: a versatile computerized approach for characterization of ligand-binding systems.配体:一种用于表征配体结合系统的通用计算机化方法。
Anal Biochem. 1980 Sep 1;107(1):220-39. doi: 10.1016/0003-2697(80)90515-1.
8
Inotropic and electrophysiological actions of verapamil and D 600 in mammalian myocardium. III. Effects of the optical isomers on transmembrane action potentials.维拉帕米和D 600对哺乳动物心肌的变力性及电生理作用。III. 光学异构体对跨膜动作电位的影响。
Naunyn Schmiedebergs Arch Pharmacol. 1975;290(1):81-97. doi: 10.1007/BF00499991.
9
Inotropic and electrophysiological actions of verapamil and D 600 in mammalian myocardium. II. Pattern of inotropic effects of the optical isomers.维拉帕米和D 600对哺乳动物心肌的变力性和电生理作用。II. 光学异构体的变力性效应模式。
Naunyn Schmiedebergs Arch Pharmacol. 1975;290(1):69-80. doi: 10.1007/BF00499990.